GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Both are Novo Nordisk’s semaglutide and pharmacologically identical, but they are NOT interchangeable in India. Ozempic is DCGI-approved for type 2 diabetes (max weekly dose 2 mg), Wegovy is approved for chronic weight management (titrated up to 2.4 mg). If your goal is weight loss without diabetes, Wegovy is the on-label choice. If you have T2D, Ozempic is on-label and often cheaper.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Ozempic vs Wegovy — at a glance

AttributeOzempicWegovy
Active ingredientSemaglutideSemaglutide
Indication (India)Type 2 DiabetesObesity / Chronic Weight Management
DCGI approvalPre-20262025–2026
Available dose strengths0.25 mg, 0.5 mg, 1 mg, 2 mg0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Maintenance dose1–2 mg weekly2.4 mg weekly
Form factorFlexTouch pre-filled penPre-filled pen (single-use)
FrequencyOnce weeklyOnce weekly
Approx. monthly price (India, 2026)₹5,660 – ₹9,100₹5,660 – ₹16,400
Maximum approved weight loss data~6% at 1 mg / ~10% at 2 mg~15% at 2.4 mg over 68 weeks (STEP-1)
Prescription requiredYes (Schedule H)Yes (Schedule H)
Insurance reimbursement (India)Rarely coveredAlmost never covered for weight loss

Efficacy — what the trials show

Ozempic

Ozempic’s primary outcome data comes from the SUSTAIN trials. SUSTAIN-7 showed mean HbA1c reduction of 1.4–1.8% at 1 mg vs comparator diabetes drugs, with weight reduction of 4.5–6.5 kg as a secondary endpoint. The 2 mg dose, approved later, extends weight loss to ~10% in patients with T2D when combined with metformin.

Wegovy

Wegovy’s pivotal evidence is the STEP-1 trial (NEJM 2021): adults with overweight/obesity without diabetes lost a mean 14.9% body weight over 68 weeks on 2.4 mg, versus 2.4% on placebo. STEP-2 showed similar efficacy in patients with T2D. The SELECT trial extended approval rationale: 20% lower MACE in patients with established cardiovascular disease and obesity.

Cost in India (2026)

Ozempic

Post-April 2026 price cuts brought Ozempic’s monthly cost to roughly ₹5,660–9,100, depending on dose and pharmacy. For an Indian patient with T2D on 1 mg weekly, expect ~₹6,000–7,500/month. Some hospital pharmacies stock it at MRP only; private pharmacies discount 5–10%.

Wegovy

Wegovy in India runs ₹5,660–16,400/month, scaling with dose. The 2.4 mg target dose (5 pens/month) is closer to the upper end. Generic Indian semaglutides (Sundae, Noveltreat, Obeda, etc) at the same molecular dose are 3–5× cheaper — discussed in the FAQ below.

Side effects

Ozempic

Most-common side effects (>10% of patients) on Ozempic: nausea, diarrhea, vomiting, abdominal pain, constipation. These peak during titration and usually subside after 4–8 weeks at a stable dose. Indian patients report slightly higher GI intolerance, partially attributable to spicier/oilier diets during titration. Rare but important: pancreatitis, gallbladder events, retinopathy in poorly-controlled diabetics.

Wegovy

Identical molecule, so the side-effect profile mirrors Ozempic. STEP-1 data showed nausea in 44%, diarrhea in 32%, vomiting in 25%, mostly during dose escalation. At 2.4 mg the rates are slightly higher than Ozempic’s 2 mg. Muscle mass loss in long-term users is an emerging concern — discussed in our side-effects deep dive.

Which one should you consider?

Pick Ozempic if

  • ✓You have diagnosed type 2 diabetes
  • ✓Cost is a significant constraint
  • ✓Your doctor is more familiar with Ozempic
  • ✓You don’t need doses above 2 mg

Pick Wegovy if

  • ✓Your primary goal is weight management, not glucose control
  • ✓You meet the Indian BMI criteria for obesity (≥25 with comorbidities, or ≥27.5 absolute)
  • ✓You may need to titrate to 2.4 mg for maximal weight loss
  • ✓You’re documenting weight-loss therapy for insurance or workplace wellness records

Frequently asked questions

Can I take Ozempic for weight loss in India even though it’s approved for diabetes?+
Off-label prescribing is at your doctor’s discretion in India. Many endocrinologists do prescribe Ozempic for weight loss in obese patients without diabetes — but it’s tougher to justify if pure obesity is the indication, and the on-label choice for weight management is Wegovy. The molecule is identical; the regulatory label is the difference.
Is Wegovy better than Ozempic for weight loss?+
For pure weight loss outcomes in non-diabetics, Wegovy delivers slightly more (~15% body weight reduction at 2.4 mg over 68 weeks per STEP-1). Ozempic’s max approved dose tops out at 2 mg, with corresponding weight loss closer to 10%. If your goal is maximum non-surgical weight loss, the higher Wegovy dose is the clinical advantage.
Why is Wegovy more expensive than Ozempic in India?+
Wegovy uses a higher-dose pen (up to 2.4 mg per week vs Ozempic’s 2 mg), and it’s priced for the obesity indication where Indian patients self-pay (rarely insured). Ozempic, being a diabetes drug, often runs through structured prescriptions and bulk pharmacy procurement, which keeps the per-month cost somewhat lower.
Can I switch from Ozempic to Wegovy?+
Yes, but only under medical supervision. The transition usually involves matching the current Ozempic dose to the equivalent Wegovy strength, then continuing the titration plan if needed. If you’ve been on 2 mg Ozempic and want to escalate to 2.4 mg Wegovy for additional weight loss, your doctor will manage that step-up over 4 weeks.
Are Indian generic semaglutides (Sundae, Noveltreat, Obeda) the same molecule as Ozempic and Wegovy?+
Yes — the active ingredient is the same semaglutide. Indian DCGI-approved generics are bioequivalent (≥ 90% confidence interval per DCGI guidelines) and 3–5× cheaper. The differences are mostly in pen design and titration packaging. For cost-sensitive patients, generics are a legitimate option; speak to your doctor about brand selection.
Does either Ozempic or Wegovy work better for PCOS-driven weight gain?+
Clinical data for PCOS specifically is limited but emerging. Both work via the same GLP-1 receptor mechanism, and both have been used off-label for PCOS-associated weight gain in India. Wegovy’s higher dose ceiling may produce more weight reduction. The decision is patient-specific — weight, BMI, comorbidities, and insulin resistance matter more than which brand.
Will I gain the weight back if I stop Ozempic or Wegovy?+
Likely yes, in significant part. The STEP-4 trial showed that patients who discontinued semaglutide regained about two-thirds of lost weight within 12 months. This applies to both Ozempic and Wegovy because the molecule is identical. Long-term success depends on either continuing therapy or pairing it with sustainable lifestyle changes during the treatment window.

Related comparisons

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide in India — Class-Level Comparison

Ozempic vs Mounjaro

Ozempic vs Mounjaro in India — For Diabetes and Weight

Mounjaro vs Wegovy

Mounjaro vs Wegovy in India — Which Loses More Weight?

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.